Helix BioPharma Corp. reported a net loss and total comprehensive loss of $3,354,000, or $0.04 per common share, for the fiscal year ended July 31, 2026, a significant improvement from the $5,205,000 loss, or $0.09 per share, recorded in the prior year. The reduction in the annual deficit, announced via NEWMEDIAWIRE, reflects a deliberate contraction of spending as the clinical-stage oncology company preserves capital for its lead pipeline assets.
The most consequential disclosure in the results is the company’s liquidity position. As of July 31, 2026, Helix held cash reserves of just $804,000, a working capital deficiency of $4,181,000, and an accumulated deficit of $219,230,000. Management stated plainly that these cash reserves are insufficient to meet anticipated working capital and capital expenditure requirements over the next twelve months or to complete current research and development initiatives, making the securing of additional funds of utmost importance.
The company’s financing strategy now hinges on securing bridge financing to support near-term corporate objectives and prepare for a larger subsequent financing. That larger raise is intended to fund the next stages of clinical development, including the planned Phase Ib/randomized Phase II study of L-DOS47 in combination with pembrolizumab as first-line therapy in non-small cell lung cancer. The timing and execution of these activities remain contingent on securing sufficient financing and meeting regulatory requirements. A previous proposed $33,370,000 equity financing collapsed in December 2025 after the subscriber declared bankruptcy, leaving the company without those expected proceeds.
Research and development expenses fell 54% to $1,620,000, driven primarily by a $1,771,000 reduction in program expenditures reflecting the wind-down of prior clinical activities, including the LDOS006 study in metastatic pancreatic adenocarcinoma, and the deferral of external service provider engagement for L-DOS47 and other programs pending successful fundraising. The full breakdown of these expenses is detailed in Table 1. Operating, general and administration expenses rose 10% to $2,019,000, largely due to stock-based compensation from a May 2026 option grant, as shown in Table 2.
Despite the financial strain, Helix continued to strengthen its leadership and clinical organization. The company appointed Markus Loeffler as Chief Medical Officer, bringing over 30 years of oncology drug development experience, alongside Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations. It also reconstituted its board under new Chair Karen Krumeich, with five of six directors now independent. On the science side, Helix presented preclinical data on its CEACAM6-directed antibody-drug conjugate program at the World ADC London conference and extended its research agreement with metaShape Pharma AG for LEUMUNA™ through December 2028.
The company’s audited financial statements and management’s discussion and analysis are available under its profile on SEDAR+ and on its website at www.helixbiopharma.com. The full statement of financial position and statement of net loss are summarized in Table 3. With the closing share price at $0.92 on October 8, 2026, below the $1.42 debenture conversion price, and convertible debentures carrying a 25% annual interest rate maturing in July 2027, the company’s ability to close its planned bridge financing will determine whether its clinical programs can advance.
